Ascorbic acid co-administration with a low dose of diminazene aceturate inhibits the in vitro growth of Theileria equi, and the in vivo growth of Babesia microti
Ascorbic acid co-administration with a low dose of diminazene aceturate inhibits the in vitro growth of Theileria equi, and the in vivo growth of Babesia microti
复制标题
抗坏血酸与低剂量二胺脒乙酸酯共同给药可抑制马泰勒虫的体外生长和田鼠巴贝虫的体内生长
DOI：
10.1016/j.parint.2022.102596
复制
发表时间：
2022
影响因子：
1.9
通讯作者：
Igarashi Ikuo
中科院分区：
文献类型：
--
作者：
Rizk Mohamed Abdo;El-Sayed Shimaa Abd El-Salam;Igarashi Ikuo
本文研究了抗坏血酸对牛巴氏杆菌（Bartonella bovis）、二联Baconia bigemina、B. caballi和马泰勒虫（T. equi），以及针对布鲁氏杆菌属微生物菌素小鼠的作用。抗坏血酸在体外和体内的抗血浆效力用基于荧光的SYBR绿色I试验来评估。应用原子对指纹图谱技术（APfp），研究了抗坏血酸与常用的抗巴贝虫药物醋酸亚胺嗪（DA）和二丙酸亚胺威（ID）的结构相似性。牛至T.用Chou-Talalay法测定抗坏血酸和DA的相互作用。抗坏血酸抑制。bovis，牛湾（B. bigemina，T. equi和B.在体外培养条件下，细胞生长呈剂量依赖性。APfp结果表明，抗坏血酸和DA具有最大的结构相似性（MSS）。在AT上。在离体培养条件下，抗坏血酸与DA具有协同作用，其结合指数为0.28。维生素C与低剂量DA（6.25 mg kg−1）联合作用可使微生物量减少41%。结果表明，抗坏血酸/DA可能是治疗T.因此，它可以用来克服巴贝斯虫对全剂量常规使用的抗巴贝斯虫药物DA的耐药性。
In the current investigation, the effect of ascorbic acid on thein vitrogrowth of several piroplasm including Babesiabovis (Bartonella bovis), Baconia bigemina, B. caballi,and Theileria equi(T. equi), as well as against Brucellamicrotiin mice was assessed. The antipiroplasm efficacy of ascorbic acidin vitroandin vivowas assessed using a fluorescence-based SYBR Green I test. Using atom pair fingerprint (APfp), we investigated the structural similarity between ascorbic acid and the commonly used antibabesial medicines, diminazene aceturate (DA) and imidocarb dipropionate (ID).In vitrocultures ofB. bovisandT. equiwere utilized to determine the ascorbic acid and DA interaction using the Chou–Talalay method. Ascorbic acid inhibitedB. bovis, B. bigemina, T. equi, andB. caballigrowthin vitroin a dose-dependent manner. The APfp results revealed that ascorbic acid and DA have a maximum structural similarity (MSS). On aT. equiculturein vitro, ascorbic acid showed a synergistic interaction with DA, with a combination index of 0.28.B. microtigrowth was decreased by 41%in vivousing ascorbic acid combined with a very low dosage of DA (6.25 mg kg−1). The results imply that ascorbic acid /DA could be a viable combination therapy for the treatment ofT. equiand that it could be utilized to overcome the resistance ofBabesiaparasites to full doses of the regularly used antibabesial medication, DA.